☆ 4.4 Letter

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies

LANCET RHEUMATOLOGY (2021)

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Nicola P. Klein et al.

Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Ana C. Medeiros-Ribeiro et al.

Summary: In a large prospective phase 4 trial, vaccination with CoronaVac, an inactivated SARS-CoV-2 vaccine, elicited significantly lower virus-specific IgG antibodies and neutralizing antibodies in patients with autoimmune rheumatic diseases than in age- and sex-matched healthy control trial participants.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

Antiphospholipid Antibodies and Infection: Non Nova Sed Nove

Savino Sciascia et al.

Summary: The presence of antiphospholipid antibodies in COVID-19 patients may contribute to a pro-coagulant state, but differs from patients with overt APS. Therefore, caution is needed in interpreting and generalizing the role of aPL in the management of COVID-19 patients. Additional well-designed clinical studies are necessary before introducing aPL testing as routine in COVID-19 patients.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Immunology

Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study

Cinzia Rotondo et al.

Summary: The risk of developing adverse events (AEs) after the first dose of anti-COVID-19 vaccine was lower in older patients with autoimmune/chronic inflammatory RD (Au/c-In-RD) and in those with complete disease control. The safety profile of COVID-19 vaccines in RD patients appeared to be favorable, with common reported AEs including site injection pain, headache, fever, myalgia, and fatigue.

VACCINES (2021)

添加到收藏夹

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies

相关参考文献

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial

Antiphospholipid Antibodies and Infection: Non Nova Sed Nove

Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study

导出引文

分享论文